Freezing plus immunotherapy for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment that freezes part of the stomach tumor (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) as continued therapy for advanced stomach cancer. It may help people whose cancer has spread and who cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 4 stomach cancer that cannot be removed by surgery
- You are able to start first-line treatment with sintilimab plus chemotherapy
- You are 18 years or older
- Your main tumor is 6 cm or smaller
- Your liver, kidney, and blood counts are within safe levels
- You are not pregnant and do not plan to become pregnant
- You do not have active infections like HIV, hepatitis B or C, or tuberculosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a freezing technique (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) for people with advanced stomach cancer that has spread or cannot be removed by surgery. It's for those whose cancer has continued to grow after one or two types of chemotherapy.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.